Title |
Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
|
---|---|
Published by |
John Wiley & Sons, Ltd, September 2013
|
DOI | 10.1002/14651858.cd010288.pub2 |
Pubmed ID | |
Authors |
Jat, Kana R, Walia, Dinesh K, Khairwa, Anju |
Abstract |
Cystic fibrosis is an autosomal recessive multisystem disorder with an approximate prevalence of 1 in 3500 live births. Allergic bronchopulmonary aspergillosis is a lung disease caused by aspergillus-induced hypersensitivity with a prevalence of 2% to 15% in people with cystic fibrosis. The mainstay of treatment includes corticosteroids and itraconazole. The treatment with corticosteroids for prolonged periods of time, or repeatedly for exacerbations of allergic bronchopulmonary aspergillosis, may lead to many adverse effects. The monoclonal anti-IgE antibody, omalizumab, has improved asthma control in severely allergic asthmatics. The drug is given as a subcutaneous injection every two to four weeks. Since allergic bronchopulmonary aspergillosis is also a condition resulting from hypersensitivity to specific allergens, as in asthma, it may be a candidate for therapy using anti-IgE antibodies. Therefore, anti-IgE therapy, using agents like omalizumab, may be a potential therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Kuwait | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 26 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 23% |
Other | 4 | 15% |
Student > Ph. D. Student | 3 | 12% |
Student > Postgraduate | 3 | 12% |
Lecturer | 2 | 8% |
Other | 6 | 23% |
Unknown | 2 | 8% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 58% |
Biochemistry, Genetics and Molecular Biology | 3 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Arts and Humanities | 1 | 4% |
Nursing and Health Professions | 1 | 4% |
Other | 3 | 12% |
Unknown | 2 | 8% |